Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

BCS-like Bogoliubov quasiparticles in high-T(c) superconductors observed by angle-resolved photoemission spectroscopy.

Physical review letters·2003

Same author

Low energy excitation and scaling in Bi(2)Sr(2)Ca(n-1)Cu(n)O(2n+4) (n=1-3): angle-resolved photoemission spectroscopy.

Physical review letters·2002

Same author

Serum thymidine kinase and soluble interleukin-2 receptor predict recurrence of malignant lymphoma.

Annals of hematology·2002

Same author

[Clinical significance of WHO classification and MDS 2000 classification in myelodysplastic syndromes].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2002

Same author

The molecular basis for the alternative stable phenotype in a behavioral mutant of Paramecium tetraurelia.

Genes & genetic systems·2002

Same author

Monocyte chemotactic protein-1 in the vitreous of patients with proliferative diabetic retinopathy.

Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde·2001

Search research articles

Related Experiment Video

Updated: Jul 18, 2026

Modeling Chemotherapy Resistant Leukemia In Vitro

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

[Hairy cell leukemia successfully treated with deoxycoformycin].

A Matsuda¹, I Jinnai, H Mizuno

¹First Department of Internal Medicine, Saitama Medical School.

[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology

|November 1, 1992

Summary

Deoxycoformycin (DCF) effectively treated hairy cell leukemia (HCL) in a Japanese patient, resolving splenomegaly and normalizing blood counts. This suggests DCF may be a viable treatment for HCL in Japanese populations.

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Related Experiment Videos

Last Updated: Jul 18, 2026

Modeling Chemotherapy Resistant Leukemia In Vitro

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Area of Science:

Hematology
Oncology
Pharmacology

Background:

Hairy cell leukemia (HCL) is a rare B-cell chronic lymphoid leukemia.
Treatment options for HCL include chemotherapy and targeted therapies.
Deoxycoformycin (DCF) has shown efficacy in Western HCL patients.

Observation:

A 45-year-old male presented with fatigue, fever, hepatosplenomegaly, and pancytopenia.
Peripheral blood and bone marrow revealed a high percentage of hairy cells and myelofibrosis.
Hairy cells were positive for tartrate-resistant acid phosphatase (TRAP) and specific surface markers (CD11c, CD25).

Findings:

HCL diagnosis confirmed by morphology, cytochemistry, and immunophenotyping.
Treatment with deoxycoformycin (DCF) resulted in complete resolution of splenomegaly and peripheral hairy cells.
Hematological parameters normalized, with only mild residual hairy cells and myelofibrosis in bone marrow.

Implications:

DCF demonstrates significant efficacy in treating hairy cell leukemia.
This case suggests DCF may be an effective therapeutic option for Japanese patients with HCL.
Further investigation is warranted to confirm DCF's effectiveness in the Japanese HCL population, considering potential hematologic differences.